Impact of prophylactic vaccination against human papillomavirus infection

被引:0
|
作者
Elbasha, Elamin H. [1 ]
机构
[1] Merck Res Labs, N Wales, PA 19454 USA
关键词
HPV; HPV disease; cancer; vaccine; mathematical model; local stability; endemic equilibrium; reproduction number;
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Human papillornavirus (HPV) is the primary cause of cervical carcinoma and its precursor lesions. Prophylactic vaccines against oncogenic and warts-causing genital HPV types are currently under development and are expected to be available in the near future. This paper presents a two-sex, deterministic model for assessing the potential impact of a prophylactic HPV vaccine that has five biological modes of action: "take", "degree", "duration", "infectiousness", and "clearance". The model is based on the susceptible-infective-removed (SIR) compartmental structure. Important epidemiological thresholds such as the basic and vaccinated reproduction numbers and a measure of vaccine impact are derived. We find that if the vaccinated reproduction number is greater than unity, there is a locally unstable disease-free equilibrium and a unique endemic equilibrium. If the vaccinated reproduction number is less than unity, HPV will be eliminated. We use analytical and numerical methods to analyze the importance of various vaccine efficacy parameters as well as compare gender-specific and universal vaccination.
引用
收藏
页码:113 / 127
页数:15
相关论文
共 50 条
  • [1] Prophylactic vaccination against human papillomavirus
    Derancourt, C.
    [J]. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2007, 134 (11): : 882 - 885
  • [2] Prophylactic vaccination against human papillomavirus.
    Roden, R
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (11) : 2785S - 2785S
  • [3] ANALYSIS OF THE IMPACT OF PROPHYLACTIC VACCINATION AGAINST HUMAN PAPILLOMAVIRUS INFECTION USING A DYNAMIC-MODELLING APPROACH
    Westra, T.
    Nijman, H.
    Wilschut, J.
    Daemen, T.
    Postma, M.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A411 - A411
  • [4] Impact of Vaccination against human Papillomavirus
    Schoenfeld, V.
    Marquis, A.
    Nitschmann, S.
    [J]. INTERNIST, 2020, 61 (03): : 333 - 335
  • [5] Vaccination against human papillomavirus in Switzerland: simulation of the impact on infection rates
    Berchtold, Andre
    Michaud, Pierre-Andre
    Nardelli-Haefliger, Denise
    Suris, Joan-Carles
    [J]. INTERNATIONAL JOURNAL OF PUBLIC HEALTH, 2010, 55 (01) : 25 - 34
  • [6] The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer
    Guo, Theresa
    Eisele, David W.
    Fakhry, Carole
    [J]. CANCER, 2016, 122 (15) : 2313 - 2323
  • [7] Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials
    Rambout, Lisa
    Hopkins, Laura
    Hutton, Brian
    Fergusson, Dean
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2007, 177 (05) : 469 - 479
  • [8] Prophylactic human papillomavirus vaccination update
    Fiander, Alison
    [J]. OBSTETRICIAN & GYNAECOLOGIST, 2009, 11 (02): : 133 - 135
  • [9] PROPHYLACTIC AND THERAPEUTIC VACCINATION AGAINST A MUCOSAL PAPILLOMAVIRUS
    CAMPO, MS
    GRINDLAY, GJ
    ONEIL, BW
    CHANDRACHUD, LM
    MCGARVIE, GM
    JARRETT, WFH
    [J]. JOURNAL OF GENERAL VIROLOGY, 1993, 74 : 945 - 953
  • [10] Prophylactic human papillomavirus vaccination against cervical cancer: a summarised resource for clinicians
    Lindeque, B. G.
    Dreyer, G.
    Botha, H.
    Moodley, T.
    Mouton, A.
    Moodley, M.
    Soeters, R.
    Smith, T.
    Cooreman, N.
    Guidozzi, F.
    Hoosen, A.
    Koller, B.
    Turner, C.
    Moodley, J.
    Godi, N. P.
    Voyi, K.
    Slavik, T.
    Whittaker, J.
    Williamsen, A.
    Rogers, L.
    [J]. SOUTHERN AFRICAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2011, 3 (01) : 39 - 42